tiprankstipranks
Advertisement
Advertisement
Kalaris Therapeutics reports positive Phase 1a TH103 results
PremiumCompany AnnouncementsKalaris Therapeutics reports positive Phase 1a TH103 results
4d ago
Kalaris Therapeutics reports additional data from ascending dose trial of TH103
Premium
The Fly
Kalaris Therapeutics reports additional data from ascending dose trial of TH103
4d ago
Kalaris Therapeutics Announces Board and Audit Committee Changes
Premium
Company Announcements
Kalaris Therapeutics Announces Board and Audit Committee Changes
15d ago
Kalaris Therapeutics, Inc. (KLRS) Q1 Earnings Cheat Sheet
PremiumPre-EarningsKalaris Therapeutics, Inc. (KLRS) Q1 Earnings Cheat Sheet
2M ago
Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls
Premium
The Fly
Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls
2M ago
Wedbush bullish on Kalaris Therapeutics, initiates with an Outperform
Premium
The Fly
Wedbush bullish on Kalaris Therapeutics, initiates with an Outperform
2M ago
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
PremiumCompany AnnouncementsKalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
3M ago
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
Premium
Ratings
Kalaris Therapeutics: Early TH103 Data in nAMD Support Buy Rating and Favorable Risk/Reward Despite Manufacturing Hurdles
4M ago
Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
Premium
The Fly
Kalaris Therapeutics reports FY25 EPS ($2.85), consensus ($3.70)
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100